Utah Medical Products (UTMD) AI Stock Analysis

123 Followers

Utah Medical Products

(NASDAQ:UTMD)

Select Model

Rating:68Neutral

Price Target:$78.00▲(8.38% Upside)

Action:downgraded

Date:11/14/26

Utah Medical Products earns a score of 68. The most impactful strength is the company's bulletproof, debt-free balance sheet and high operational efficiency. Furthermore, the recent acquisition of Orion Medical Supplies acts as a significant catalyst to combat recent revenue declines caused by international weakness. However, persistent top-line contraction and lackluster near-term technical momentum keep the overall score in check. The stock is fairly valued, balancing exceptional profitability against the need for renewed sales growth.

Positive Factors

Balance Sheet StrengthMinimal leverage materially reduces financial risk and preserves flexibility to fund operations, acquisitions, dividends, or buybacks without a meaningful debt burden. Stable equity and healthy ROE further support resilience if operating conditions remain soft.

Negative Factors

Revenue ContractionRevenue has declined materially over several years, indicating that the core business is not currently expanding. Persistent top-line contraction can reduce operating leverage, constrain reinvestment, and make future earnings growth harder to sustain.

Utah Medical Products Key Performance Indicators (KPIs)

Revenue by Geography

Chart Insights

Data provided by:

The Fly

Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $205.05M
Dividend Yield: 1.72%
Average Volume (3M): 36.82K
Price to Earnings (P/E): 21.5
Beta (1Y): 0.41
Revenue Growth: -9.62%
EPS Growth: -5.65%
Country: US
Employees: 146
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Utah Medical Products Business Overview & Revenue Model

Company Description

Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and d...

Utah Medical Products Financial Statement Overview

Summary

Utah Medical Products boasts a pristine, debt-free balance sheet and excellent cash conversion alongside robust profit margins. However, top-line revenue and cash flows have faced notable declines, driven by persistent weakness in overseas demand and a structural shift away from Blood Pressure Monitoring products. While domestic revenue has stabilized, future growth remains heavily dependent on a recovery in Neonatal and core surgical categories.

Income Statement

50Neutral

Balance Sheet

90Very Positive

Cash Flow

75Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	34.92M	38.52M	40.90M	50.22M	52.28M	49.05M
Gross Profit	20.14M	22.00M	24.14M	30.04M	32.20M	30.92M
EBITDA	14.87M	17.06M	19.65M	24.75M	27.74M	26.34M
Net Income	10.64M	11.29M	13.87M	16.64M	16.47M	14.79M
Balance Sheet
Total Assets	128.50M	122.54M	122.54M	135.46M	123.87M	115.64M
Cash, Cash Equivalents and Short-Term Investments	85.20M	85.76M	82.98M	92.87M	75.05M	60.97M
Total Debt	180.00K	225.00K	338.00K	295.00K	341.00K	396.00K
Total Liabilities	5.22M	3.27M	5.11M	7.14M	9.62M	8.50M
Stockholders Equity	123.28M	119.27M	117.43M	128.31M	114.25M	107.14M
Cash Flow
Free Cash Flow	10.86M	14.32M	14.60M	21.64M	20.33M	20.65M
Operating Cash Flow	11.47M	14.69M	14.83M	22.28M	21.15M	21.20M
Investing Cash Flow	-4.65M	-371.00K	-208.00K	-639.00K	-818.00K	-552.00K
Financing Cash Flow	-5.73M	-12.34M	-23.84M	-4.17M	-5.48M	-10.90M

Utah Medical Products Technical Analysis

Technical Analysis SentimentNegative

Last Price71.97

Price Trends

50DMA72.97Negative

100DMA71.62Positive

200DMA68.18Positive

Market Momentum

MACD-0.19Negative

RSI48.05Neutral

STOCH79.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Negative. The current price of 71.97 is below the 20-day moving average (MA) of 72.23, below the 50-day MA of 72.97, and above the 200-day MA of 68.18, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 48.05 is Neutral, neither overbought nor oversold. The STOCH value of 79.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UTMD.

Utah Medical Products Risk Analysis

Utah Medical Products disclosed 10 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Utah Medical Products Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

UTMD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	70Outperform	$294.89M	31.30	15.77%	―	2.40%	76.01%
UTMD	68Neutral	$205.05M	21.54	8.78%	1.72%	-9.62%	-5.65%
KRMD	57Neutral	$160.49M	-209.04	0.00%	―	18.43%	78.07%
SMTI	52Neutral	$297.06M	-90.54	-42.22%	―	9.82%	91.93%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

UTMD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
UTMD	Utah Medical Products	71.97	18.08	33.54%
INFU	InfuSystem Holdings, Inc.	14.72	5.40	57.94%
KRMD	Repro-Med Systems, Inc.	3.70	-0.79	-17.59%
SMTI	Sanara MedTech	32.35	11.28	53.54%

Utah Medical Products Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A Transactions

Utah Medical Products Expands Via Orion Medical Acquisition

Positive

Aug 31, 2026

On August 31, 2026, Femcare Ltd., a wholly owned subsidiary of Utah Medical Products, Inc., completed the acquisition of all common shares of UK-based Orion Medical Supplies Ltd, a niche assembler and distributor of harm reduction medical device kits...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026

Utah Medical Products AI Stock Analysis